GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Cash-to-Debt

Bangkok Genomics Innovation PCL (BKK:BKGI) Cash-to-Debt : 17.61 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bangkok Genomics Innovation PCL's cash to debt ratio for the quarter that ended in Mar. 2024 was 17.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bangkok Genomics Innovation PCL could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Cash-to-Debt or its related term are showing as below:

BKK:BKGI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.89   Med: 4.79   Max: 17.61
Current: 17.61

During the past 5 years, Bangkok Genomics Innovation PCL's highest Cash to Debt Ratio was 17.61. The lowest was 0.89. And the median was 4.79.

BKK:BKGI's Cash-to-Debt is ranked better than
85.46% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.27 vs BKK:BKGI: 17.61

Bangkok Genomics Innovation PCL Cash-to-Debt Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bangkok Genomics Innovation PCL Cash-to-Debt Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
0.49 0.89 4.76 4.69 6.99

Bangkok Genomics Innovation PCL Quarterly Data
Dec20 Dec21 Mar22 Dec22 Mar23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial N/A 4.69 4.82 6.99 17.61

Competitive Comparison of Bangkok Genomics Innovation PCL's Cash-to-Debt

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bangkok Genomics Innovation PCL's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Cash-to-Debt falls into.



Bangkok Genomics Innovation PCL Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bangkok Genomics Innovation PCL's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Bangkok Genomics Innovation PCL's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bangkok Genomics Innovation PCL  (BKK:BKGI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Bangkok Genomics Innovation PCL Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).

Bangkok Genomics Innovation PCL (BKK:BKGI) Headlines